메디채널

주메뉴 바로가기
본문 바로가기

기상청 제공

닫기

라이프

Noul Supplies AI Diagnostic Platform miLab™ to Charité, Europe's Leading University Hospital

Prestigious Nobel Prize–winning institution confirms adoption of miLab™ following clinical evaluation "A milestone signaling broader adoption in advanced global healthcare markets" YONGIN, South Korea, Oct. 28, 2025 -- Noul Co., Ltd.(CEO David Lim), an AI-driven blood and cancer diagnostics company, announced the supply of its AI-based malaria diagnostic solution miLab™ MAL to Charité – Universitätsmedizin Berlin, Germany's largest and most prestigious university hospital. Founded over 300 years ago, Charité is ranked No.
- 김갑성 기자
- 2025-10-28 21:00
SI GROUP OPENS NEW INNOVATION CENTER

State-of-the-art facility expands company's global research and development capabilities THE WOODLANDS, Texas, Oct. 28, 2025 -- SI Group, a leading global developer and manufacturer of performance additives, process solutions, and chemical intermediates, announced the official opening of its European Innovation Centre (EIC) in Four Ashes, United Kingdom. This milestone marks an important expansion of SI Group's global innovation network, strengthening R&D and application development to better serve customers worldwide. The new state-of-the-art facility is equipped wi
- 김갑성 기자
- 2025-10-28 20:30
Sisram Medical Delivers Strong Third-Quarter 2025 Performance with Robust Momentum Across Key Markets and Core Businesses

HONG KONG, Oct. 28, 2025 -- Sisram Medical Ltd (the "Company" or "Sisram", 1696.HK; together with its subsidiaries collectively referred to as the "Group"), a global consumer wellness group offering Energy-Based Devices (EBD), injectables, and other complementary solutions, today announced its business update for the third quarter of 2025, highlighting solid revenue growth and accelerated momentum across core product segments and key markets. In the third quarter of 2025, the Company achieved double-digit revenue growth compared to the same period last yea
- 김갑성 기자
- 2025-10-28 20:29
Fosun Pharma Announces 2025Q3 Financial Results

[ 메디채널 김갑성 기자 ] Innovative Achievements Continue to Come to Fruition, Revenue from Innovative Drugs Exceeding RMB6,700 Million in The First Three Quarters of 2025 SHANGHAI, Oct. 28, 2025 -- On October 28, 2025, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. ("Fosun Pharma" or "the Group"; SSE: 600196, HKEX: 02196), a leading innovation-driven global healthcare company, announced its financial results for the first three quarters of 2025. In the first three quarters of 2025, Fosun Pharma achieved operating revenue of RMB29,393 million, net profit attributable to s
- 김갑성 기자
- 2025-10-28 20:11
South Korea's Leading Hair Loss Treatment Company, AESMED Co., Ltd., to Participate in Cosmoprof Asia Hong Kong 2025

[ 메디채널 김갑성 기자 ] AESMED to Focus on Promoting the 1111 Hair Care Day Campaign SEOUL, South Korea, Oct. 28, 2025 -- AESMED Co., Ltd., a leading hair loss treatment company in South Korea, announced its participation in Cosmoprof Asia Hong Kong 2025, the largest B2B international beauty trade fair in Asia, to be held from November 12–14, 2025, at the Hong Kong Convention & Exhibition Centre. Cosmoprof Asia brings together global beauty leaders to present the latest technologies, product innovations, and solutions, serving as a key platform shaping the beauty industry worldwide.
- 김갑성 기자
- 2025-10-28 19:37
Myrio Therapeutics Announces Collaboration with Leading Research Institutions to Advance Solid Tumor T cell Immunotherapeutics

Myrio Therapeutics, the University of Pennsylvania Perelman School of Medicine, and NYU Langone Health have entered a research collaboration to accelerate the development of next-generation T cell immunotherapies Partnership with T cell experts Daniel J Powell Jr., PhD, and Mark Yarmarkovich, PhD PHILADELPHIA, NEW YORK and MELBOURNE, Australia, Oct. 28, 2025 -- Myrio Therapeutics today announced a collaborative research partnership with the University of Pennsylvania's Perelman School of Medicine and NYU Langone Health to accelerate the development of next generation sol
- 김갑성 기자
- 2025-10-28 19:35
Ping An Reports Significant Improvements in Operating Profit in 9M 2025, Life & Health NBV Robustly Increases 46.2% YoY

Net Profit Surges 45.4% YoY in 3Q 2025 HONG KONG, SHANGHAI, Oct. 28, 2025 -- Ping An Insurance (Group) Company of China, Ltd. (hereafter "Ping An", the "Company", or the "Group", HKEX: 2318 / 82318; SSE: 601318) today announced its results for the nine months ended September 30, 2025. Despite a complex, fluid external environment, China's economy achieved steady progress amid overall stability as domestic demand potential was unleashed and development resilience was enhanced in the first nine months of 2025. Ping An focused on core financial busines
- 황정호 기자
- 2025-10-28 18:02
WuXi AppTec Looks to Extend CRDMO Platform to Saudi Arabia as It Signs Strategic MoUs with NEOM and Ministry of Health

SHANGHAI, Oct. 28, 2025 -- WuXi AppTec, a leading global pharmaceutical CRDMO (Contract Research, Development, and Manufacturing Organization), today announced it has signed two strategic memoranda of understanding (MoUs) with NEOM, the sustainable region under development in northwest Saudi Arabia and the Ministry of Health of the Kingdom of Saudi Arabia (MOH). WuXi AppTec and NEOM have agreed to collaborate to explore the localization of pharmaceutical research, development and manufacturing in Saudi Arabia. The agreement lays the groundwork for establishing world-class CRDMO facilit
- 김갑성 기자
- 2025-10-28 17:00
Xinhua Silk Road: Innovation, tradition deeply integrated on TCM trade fair in China's Zhangshu City

BEIJING, Oct. 28, 2025 -- China's Zhangshu City, a famed industrial hub of traditional Chinese medicine (TCM) for centuries, has actively promoted integration of tradition and innovation for China's traditional medicines and medical treatment on its annual TCM fair. The 56th National Medicinal Materials and Pharmaceuticals Trade Fair, which was held on October 16-18 in Zhangshu City in east China's Jiangxi Province, provided a platform for TCM experts to exchange cutting-edge ideas on topics like protection of TCM resources and application of satellite remote sensing technology
- 김갑성 기자
- 2025-10-28 16:31
LUMOSA THERAPEUTICS ANNOUNCES POSITIVE RESULTS FROM LT3001(INTRAVENOUS ODATROLTIDE) PHASE 2B CLINICAL TRIAL IN ACUTE ISCHEMIC STROKE

Results presented at the17th World Stroke Congress (WSC 2025) LT3001(Odatroltide)-202 phase 2b study met primary endpoint. No symptomatic intracranial hemorrhage occurred. Data suggest that LT3001 has the potential to provide significant clinical benefit to patients in a longer treatment window (up to 24 hours after the onset of stroke symptoms) compared to current standard of care (4.5 hours). TAIPEI, Oct. 28, 2025 -- Lumosa Therapeutics (Lumosa; 6535.TWO) today announced positive results from its Phase 2b clinical trial (LT3001-202) evaluating LT3001 (intravenous Odatroltide) i
- 김갑성 기자
- 2025-10-28 16:28

이전

1 2 3 4 5 6 7 8 9 10

많이 본 기사

최근기사

2025-11-03_MON

2025-11-02_SUN

발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.

UPDATE: 2025년 11월 03일 07시 00분